Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study

類似資料

• Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study
  著者:: Alten, Rieke, 等
  出版事項: (2017)
• Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study
  著者:: Alten, Rieke, 等
  出版事項: (2016)
• Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study
  著者:: Nüßlein, Hubert G., 等
  出版事項: (2015)
• Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study
  著者:: Nüßlein, Hubert G, 等
  出版事項: (2014)
• Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment
  著者:: Alten, Rieke, 等
  出版事項: (2014)